Private Credit ETFs: Simplifying the Case

The Simplify VettaFi Private Credit Strategy ETF (PCR) introduces an innovative ETF structure designed to provide diversified exposure to private credit, an asset class typically challenging for open-end funds due to SEC liquidity constraints. PCR achieves this by utilizing swaps to gain exposure to publicly traded Business Development Companies (BDCs) and Closed-End Funds (CEFs) that primarily invest in private loans, complemented by a proprietary credit hedging strategy. This approach offers investors a more liquid, transparent, and accessible vehicle for private credit, simplifying direct BDC/CEF selection while maintaining a competitive expense ratio compared to alternative multi-asset private credit solutions.

Analysis

Investor demand for private credit's elevated yields is driving innovation in ETF product structures designed to overcome regulatory barriers. Open-end funds, including ETFs, face a 15% limit on illiquid investments as per SEC Rule 22e-4, complicating direct access to the asset class. The market has previously offered indirect exposure through ETFs holding publicly traded alternative asset managers like Blackstone (BX) and KKR (KKR), or hybrid funds mixing public and private debt. The Simplify VettaFi Private Credit Strategy ETF (PCR) introduces a novel approach by using swaps to provide exposure to a portfolio of publicly traded Business Development Companies (BDCs) and Closed-End Funds (CEFs) that are themselves heavily invested in private credit. This strategy, guided by the VettaFi Private Credit Index, aims to capture high distributions while managing volatility. Notably, PCR includes a proprietary long/short credit hedging strategy and leverages its derivatives-based structure to offer a competitive expense ratio of 76 basis points, significantly lower than many fund-of-fund structures which range from 200-300 basis points. This structure provides investors with a liquid, transparent, and familiar ETF wrapper that mitigates the premium/discount to NAV risk often associated with direct investment in CEFs and BDCs.

Key Decisions for Investors

• Investors seeking simplified, liquid exposure to the income potential of private credit should consider PCR as an alternative to selecting individual BDCs and CEFs, which can be complex to analyze and may trade at significant discounts or premiums to NAV.
• It is crucial to understand that PCR provides synthetic exposure via swaps on BDCs and CEFs, not direct ownership of private loans; therefore, performance is tied to these underlying vehicles, the swap counterparty, and the effectiveness of the fund's proprietary credit hedging strategy.
• Before allocating capital, compare PCR's swap-based strategy and 76 basis point fee against other approaches, such as investing in asset manager stocks like BX and ARES or hybrid funds like PRIV, to determine the most suitable structure for your portfolio's risk and income objectives.